Figure and Table Legends:
Table 1. Baseline demographic characteristics of the participants who received the booster dose
Figure 1: The design of the study.
Figure2: Neutralizing antibody levels after BNT162b2 and CoronaVac booster doses. A- PRNT50 titers at baseline, one month and three months after boosters. Black lines are GMT=geometric mean titer (*P<0.001; **P<0.05). B- Changes in neutralizing antibody levels for each individual during a 3-month period. Dots represent neutralizing antibody titers for individuals in the population.
Figure 3. The proportion of specific T cell subpopulations after activation with SARS-CoV-2 S peptide pool. A-CD4+ cell ratio at baseline, one month and three months after boosters. B- CD8+ at baseline, one month and three months after boosters. Dots represent T cell ratios for individuals in the population. Black lines are median values of each population.
Figure 4. The ELISPOT results of T cells after incubation with SARS-CoV-2 S peptide pool. A - IFN-γ response at baseline, one month and three months after boosters. B- IL-2 response at baseline, one month and three months after boosters. Dots represent T cell ratios for individuals in the population, (*P<0.001; **P<0.05).
Figure 5. The ratio of CD8+CD38+CD69+ and CD4+CD38+CD69+cells after BNT162b2 and CoronaVac boosters. A-CD8+CD38+CD69+cell ratio at baseline, one month and three months after boosters.B- CD4+CD38+CD69+cell ratio at baseline, one month and three months after boosters. Dots represent T cell ratios for individuals in the population. (*P<0.05)